In a major boost to the global pharmaceutical industry Almac Group has officially opened a state-of-the-art £65 million ($83.9 million) commercial manufacturing facility at its global headquarters in Craigavon, Northern Ireland. The new facility, operated by Almac Pharma Services is set to enhance the company’s capabilities in the commercial production of oral dose treatments across a wide range of therapeutic areas.
A Cutting-Edge Facility for Advanced Pharmaceutical Manufacturing
The 100,000 sq ft facility is equipped with high-specification production suites managed by Almac Pharma Services’ expert scientific and operational teams. It features the latest pharmaceutical manufacturing technology, including expanded production scales for potent and highly potent drug products.
Construction of the facility was completed in late 2024, and after successful validation activities the production of GMP (Good Manufacturing Practice) batches is scheduled to begin on March 18th. Designed as a Center of Excellence the facility offers flexibility and adaptability to meet the diverse needs of partner companies. It also provides opportunities for clients to install custom or dedicated technology tailored to their specific pipeline requirements.
A Commitment to Innovation and Partnership
John McQuaid, President and Managing Director of Almac Pharma Services, expressed his enthusiasm about the new facility, stating, “We are thrilled to officially open our new commercial manufacturing facility at our global headquarters site. This investment underscores our commitment to supporting our clients’ growing needs with the highest level of service and expertise.”
He added, “The new facility not only expands our range of capabilities but also reinforces our position as an industry leader in pharmaceutical development and commercial manufacturing. It demonstrates our commitment to working in true partnership with our clients as we support them in bringing important new therapies to the patients we serve.”
A Milestone in Almac Group’s Global Expansion
The opening of this facility marks a significant milestone in Almac Group’s ambitious global expansion program. In 2022, the Group announced a £250 million capital investment plan aimed at creating 1,800 new jobs worldwide. Since then the projected investment has grown to over £400 million, reflecting the company’s strong growth trajectory and commitment to innovation.
What This Means for the Pharmaceutical Industry
The new facility is poised to play a pivotal role in advancing the development and commercialization of innovative therapies. By offering tailored solutions and cutting-edge technology Almac Pharma Services is well-positioned to meet the evolving needs of its clients and contribute to the delivery of life-changing treatments to patients worldwide.
A Boost for Northern Ireland’s Economy
The investment also highlights Almac Group’s commitment to its roots in Northern Ireland. The new facility is expected to create high-quality jobs and further establish the region as a hub for pharmaceutical innovation and manufacturing.
Looking Ahead
As Almac Pharma Services begins operations at the new facility, the focus will be on delivering exceptional service and supporting clients in bringing their products to market. The facility’s flexibility and advanced capabilities ensure that it will remain at the forefront of pharmaceutical manufacturing for years to come.
Why This Matters
- For the Pharmaceutical Industry: Enhanced capabilities for the production of advanced oral dose treatments.
- For Clients: Tailored solutions and cutting-edge technology to meet specific pipeline needs.
- For Northern Ireland: Economic growth and job creation in the pharmaceutical sector.
Stay tuned for more updates as Almac Group continues to lead the way in pharmaceutical innovation and manufacturing.
